Muanda FT, Weir MA, Bathini L, et al. - Researchers performed a retrospective cohort study including 15,942 patients (aged 66 years or older) with chronic kidney disease (CKD) in order to determine the risk of encephalopathy among patients with CKD initiating treatment with a higher vs lower dose of baclofen. CKD was defined as an estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m² but not receiving dialysis. Patients prescribed baclofen at greater than or equal to 20 mg per day exhibited 30-day incidence of encephalopathy of 1.11% vs 0.42% among those receiving less than 20 mg per day, a difference that was statistically significant. This indicates a possible association of baclofen use among patients with CKD, particularly at higher doses, with an increased risk of encephalopathy.